Investment Analysts’ Recent Ratings Updates for Abivax (ABVX)

Abivax (NASDAQ: ABVX) has recently received a number of price target changes and ratings updates:

• 9/26/2026 – Abivax was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/22/2026 – Abivax had its price target lowered by Truist Financial Corporation from $155.00 to $151.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Abivax had its price target lowered by Wedbush from $140.00 to $118.00. They now have a “neutral” rating on the stock.
• 9/22/2026 – Abivax had its “overweight” rating reaffirmed by Barclays PLC. They now have a $148.00 price target on the stock.
• 9/9/2026 – Abivax is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $155.00 price target on the stock.
• 9/9/2026 – Abivax was upgraded by The Goldman Sachs Group, Inc. to “strong-buy”.

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.